Cervical carcinoma is a preventable disease based on its etiopathogenesis. This relies highly on its prompt diagnosis and treatment based on effective screening and treatment methods. Knowledge of its molecular pathways will drive the use of targeted therapies in the treatment of the disease. The objectives of this review are: to explore the biology and immunology of HPV; the various molecular pathways through which oncogenic HPV destroys normal cervical cells; and targeted therapies. Several molecular pathways have been identified but the use of drugs to act on specified molecular targets are at different stages of clinical trials.
| DOI | 10.11648/j.ass.20170501.11 |
| Published in | Advances in Surgical Sciences (Volume 5, Issue 1, February 2017) |
| Page(s) | 1-6 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Cervical Cancer, Molecular Pathways, Targeted Therapies
| [1] | Boniface Uji Ago, Thomas Udagbor Agan, Etim Inyang Ekanem. Cancer of the uterine cervix at the University of Calabar teaching Hospital, Calabar Nigeria. Cancer Research Journal 2013; 1 (4): 37-40. Doi: 10.11648/j.crj.20130104.12. |
| [2] | Bouvard V, Baan R, Stralf K et al. WHO International Agency for Research on Cancer Monograph Working group. Lancet Oncol 2009; 10: 321-322. |
| [3] | Moscicki AB, Schiffman M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24 (3): 42-51. |
| [4] | Manzo-Merino J, Contreras-Paredes A, Vazquez-Ullora E, et al. The role of signaling pathways in cervical cancer and molecular therapeutic targets. Archives of Medical Research 2014; 45: 525-539. |
| [5] | Globocan.iarc.fr/old/factsheets/cancer/cervix-new.asp. accessed 26.6.15. |
| [6] | IARC Monograph on the evaluation of carcinogenic risks to humans. Volume 90. Human papilloma viruses, Lyon 2007. IARC press. |
| [7] | Peter A. Gearhart. Human Papillomaviruses. Medcape reference. Emedicine.medscape.com/219110. Accessed 10th July 2015. |
| [8] | Jose Verisssimo Fernandes, Joselio Maria Galvao de Aranjo et al. Biology and Natural history of human papilloma virus infection. Open access journal of clinical trials. Dovepress 2013; 5: 1-12. |
| [9] | Doorbar J. Molecular biology of Human papillomavirus infection and cervical cancer. Clin Sci 2006; 110: 525-41. |
| [10] | Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010; 118 (suppl 1): S12-S17. |
| [11] | Merilyn H. Hibma. The immune response to Papillomavirus during infection persistence and regression. The open virology journal 2012, 6 (suppl 2: M9) 241-248. |
| [12] | Black AP, Ardern-Jones MR, Kasprowicz V, et al. Human keratinocyte induction of rapid effector function in antigen specific memory CD4 and CD8 T cells. Eur J Immunol 2007; 37: 1485-93. |
| [13] | Poppe WA, Drijkoningen M, Ide PS, Lauweryns JM, Van Assche FA. Lymphocytes and dendritic cells in the normal uterine cervix. An immunohistochemical study. Eur J Obstet Gynecol Reprod Biol 1998; 81: 277-82. |
| [14] | Giraldo PC, de Carrolho JB, do Amaral RL. Et al. identification of immune cells by flow cytometry in vaginal lavages from women with vulvovaginitis and normal microflora. Am J Reprod Immunol 2012; 67: 198-205. |
| [15] | Kovacic MB, Katki HA, Kreimer AR, Sherman ME. Epidemiologic analysis of histologic cervical inflammation: Relationship to human papillomavirus infections. Hum Pathol 2008; 39: 1088-95. |
| [16] | John Doorbar, Nagayasu Egawa, Heather Griffin, Christian Kranjec, Isao Murakemi. Human papillomavirus molecular biology and disease association. Reviews in medical virology 2015; 25 (suppl 1): 2-23. |
| [17] | Fujii T, Majumoto N, Saito M, et al. Comparison between insitu hybridization and real-time PCR technique as a means of detecting the integrated form of human papillomavirus 16 in cervical neoplasia. Diagn. Mol. Pathol 2005; 14: 103-108. |
| [18] | Dray M, Russel P, Dalrymple C, et al. p16 (INK4a) as a complementary marker of high grade intraepithelial lesions of the uterine cervix. 1: Experience with squamous lesions in 189 consecutive cervical biopsies. Pathology 2005; 37: 112-124. |
| [19] | Oelze I, Kartenbeck J, Crusius K, and Alonso A. Human papillomavirus type 16E5 protein affectscell-cell communication in an epithelial cell line. J. Virol 1995; 69: 4489-4494. |
| [20] | Jarrad DF, Sarker S, Shi Y, Yeager TR, et al. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Can. Res 1999; 59: 2957-2964. |
| [21] | Zang Y, Fan S, Meng S, et al. BRCA1 interaction with human papillomavirus oncoproteins. J. Biol. Chem 2005; 280: 33165-33177. |
| [22] | Tang Y, Zang O, Nishitani J, Brown J, Shi S, Le AD. Overexpression of human papillomavirus type 16 oncoproteins enhance hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin. Cancer Res 2007; 13: 2568-2576. |
| [23] | Koenraad VD, Burk R. Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology 2012; 433: 216-219. |
| [24] | Spangle JM, Chen AA, Munger K. Human papillomaviruses: Pathogenesis and host immune response. Hudnail SD (ed). Viruses and human cancer. Springer science+Businessmedia New York 2014; chapter 8: 167-197. |
| [25] | Apoptosis. Wikipedia. https://en.wikipedia.org/wiki/apoptosis. |
| [26] | Peiyue J and Ying Y. The human papillomavirus oncoproteins and apoptosis (review). Exp Ther Med 2014; 7 (1): 3-7. |
| [27] | Kabsch K, and Alonso A. The human papillomavirus type 16 E5 protein impairs TRAIL and FASL-mediated apoptosis in HaCaT cells by different mechanisms. J. Virol 2002; 76: 12162-12172. |
| [28] | Perez-Plasencia C, Pina-Sanchez P, Vaca-Paniagua F, et al. Molecular events towards Wnt pathway activation in cervical cancer: Changing the balance on NKD/DVL signals. www.intechopen.com accessed 30th May 2015. |
| [29] | Chung MT, Lai HC, Sytwu HK, et al. SFRP 1&2 suppress the transformation and invasion abilities of cervical cancer cells through wnt signal pathway. Gynecol Oncol 2009; 112: 646-653. |
| [30] | Ramachandran Thavathiru et al. wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion & angiogenesis in vivo. Oncogene 2012; 31: 2725-2737. |
| [31] | Lu D, Qian, Yin X, et al. Expression of PTEN and surviving in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci 2012; 69: 143-146. |
| [32] | Chang F, Steelman LS, Le JT, et al. Signal transduction mediated by Ras/Raf/Mek/Erk pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukaemia 2003; 17: 1263-1293. |
| [33] | Mei-Yi L, Meng-Ru S. Epithelial-mesenchymal transition in cervical cancer. Am J Transl Res 2012; 4 (1): 1-13. |
| [34] | Inhibitors of signaling pathways. www.selleckchem.com. |
| [35] | Duenas-Gonzalez A, Serrano-Olvera A, Cetina L, Coronel J. New molecular targets against cervical cancer. International Journal of Women’s Health 2014; 6: 1023-1031. |
| [36] | Mungala R, Kansar H, Mungal C, Gupta RC. Withaferin –A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumour suppressor proteins in human cervical cancer cells. Carcinogenesis 2011; 32 (11): 1697-1705. |
| [37] | Yang Y, Zhao X, Chen W, et al. Effects of cidofovir on human papillomavirus-positive cervical cancer cell xenograft in nude mice. Oncol Res 2010; 18 (11-12): 519-527. |
| [38] | Global guidance for cervical cancer prevention and control. FIGO 2009. |
APA Style
Boniface Uji Ago. (2017). A Review of the Molecular Pathways of Oncogenic HPV and Targeted the Rapies in Carcinoma of the Uterine Cervix. Advances in Surgical Sciences, 5(1), 1-6. https://doi.org/10.11648/j.ass.20170501.11
ACS Style
Boniface Uji Ago. A Review of the Molecular Pathways of Oncogenic HPV and Targeted the Rapies in Carcinoma of the Uterine Cervix. Adv. Surg. Sci. 2017, 5(1), 1-6. doi: 10.11648/j.ass.20170501.11
AMA Style
Boniface Uji Ago. A Review of the Molecular Pathways of Oncogenic HPV and Targeted the Rapies in Carcinoma of the Uterine Cervix. Adv Surg Sci. 2017;5(1):1-6. doi: 10.11648/j.ass.20170501.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ass.20170501.11,
author = {Boniface Uji Ago},
title = {A Review of the Molecular Pathways of Oncogenic HPV and Targeted the Rapies in Carcinoma of the Uterine Cervix},
journal = {Advances in Surgical Sciences},
volume = {5},
number = {1},
pages = {1-6},
doi = {10.11648/j.ass.20170501.11},
url = {https://doi.org/10.11648/j.ass.20170501.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ass.20170501.11},
abstract = {Cervical carcinoma is a preventable disease based on its etiopathogenesis. This relies highly on its prompt diagnosis and treatment based on effective screening and treatment methods. Knowledge of its molecular pathways will drive the use of targeted therapies in the treatment of the disease. The objectives of this review are: to explore the biology and immunology of HPV; the various molecular pathways through which oncogenic HPV destroys normal cervical cells; and targeted therapies. Several molecular pathways have been identified but the use of drugs to act on specified molecular targets are at different stages of clinical trials.},
year = {2017}
}
TY - JOUR T1 - A Review of the Molecular Pathways of Oncogenic HPV and Targeted the Rapies in Carcinoma of the Uterine Cervix AU - Boniface Uji Ago Y1 - 2017/04/12 PY - 2017 N1 - https://doi.org/10.11648/j.ass.20170501.11 DO - 10.11648/j.ass.20170501.11 T2 - Advances in Surgical Sciences JF - Advances in Surgical Sciences JO - Advances in Surgical Sciences SP - 1 EP - 6 PB - Science Publishing Group SN - 2376-6182 UR - https://doi.org/10.11648/j.ass.20170501.11 AB - Cervical carcinoma is a preventable disease based on its etiopathogenesis. This relies highly on its prompt diagnosis and treatment based on effective screening and treatment methods. Knowledge of its molecular pathways will drive the use of targeted therapies in the treatment of the disease. The objectives of this review are: to explore the biology and immunology of HPV; the various molecular pathways through which oncogenic HPV destroys normal cervical cells; and targeted therapies. Several molecular pathways have been identified but the use of drugs to act on specified molecular targets are at different stages of clinical trials. VL - 5 IS - 1 ER -
Information
Email: